drugset / Trial / NCT02057900

Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure

NCT02057900 ↗

Phase 1 Completed 10 enrolled Assistance Publique - Hôpitaux de Paris
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the feasibility and safety of a transplantation of cardiac-committed progenitor cells derived from human embryonic stem cells in patients with severe heart failure.

Timeline

Start
2013-05-27
Primary completion
2018-03-22
Completion
2018-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Human embryonic stem cell-derived CD15+ Isl-1+ progenitors Cell therapy 8.2e+06 cells Other

Indications